IVIXF Stock - Invion Limited
Unlock GoAI Insights for IVIXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | $2.46M | $2.73M | $2.27M | $1.75M |
| Gross Profit | $-849,206 | $3.69M | $803,585 | $669,095 | $607,757 |
| Gross Margin | N/A | 150.0% | 29.4% | 29.5% | 34.7% |
| Operating Income | $-3,479,287 | $-3,784,422 | $-1,097,881 | $-1,601,834 | $-1,180,435 |
| Net Income | $-5,796,848 | $-5,627,765 | $-1,075,472 | $-1,546,596 | $-1,113,326 |
| Net Margin | N/A | -228.5% | -39.3% | -68.1% | -63.6% |
| EPS | $-0.08 | $-0.06 | $-0.02 | $-0.03 | $-0.02 |
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Visit WebsiteEarnings History & Surprises
IVIXFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q3 2025 | Sep 2, 2025 | — | $-0.05 | — | — |
Q1 2025 | Mar 4, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | $-0.03 | — | — |
Q4 2024 | Oct 28, 2024 | — | — | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.02 | — | — |
Q2 2024 | Apr 30, 2024 | — | — | — | — |
Q1 2024 | Feb 27, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 30, 2020 | — | $0.00 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $0.00 | — | — |
Q4 2018 | Dec 30, 2018 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about IVIXF
What is IVIXF's current stock price?
What is the analyst price target for IVIXF?
What sector is Invion Limited in?
What is IVIXF's market cap?
Does IVIXF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IVIXF for comparison